For research use only. Not for therapeutic Use.
POMHEX（Cat No.:I034935）is a prodrug of HEX, a potent inhibitor of enolase, an enzyme critical for glycolysis. By targeting enolase, POMHEX disrupts the glycolytic pathway, which is particularly important in cancer cells that rely heavily on glycolysis for energy production, especially in tumors with metabolic vulnerabilities. POMHEX has shown promising potential in cancer research, particularly in the treatment of gliomas and other tumors with deficiencies in oxidative metabolism. Its ability to selectively inhibit cancer cell metabolism makes it a valuable tool for developing novel cancer therapies.
| Catalog Number | I034935 |
| CAS Number | 2004714-34-3 |
| Synonyms | POMHEX; POM HEX; POM-HEX; |
| Molecular Formula | C17H30NO9P |
| Purity | 98% |
| Target | Apoptosis |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | [2,2-dimethylpropanoyloxymethoxy-(1-hydroxy-2-oxopiperidin-3-yl)phosphoryl]oxymethyl 2,2-dimethylpropanoate |
| InChI | InChI=1S/C17H30NO9P/c1-16(2,3)14(20)24-10-26-28(23,12-8-7-9-18(22)13(12)19)27-11-25-15(21)17(4,5)6/h12,22H,7-11H2,1-6H3 |
| InChIKey | TVFIFFUSHZDTKT-UHFFFAOYSA-N |
| SMILES | CC(C)(C)C(=O)OCOP(=O)(C1CCCN(C1=O)O)OCOC(=O)C(C)(C)C |
| Reference | 1: Lin YH, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, Ackroyd JJ, Georgiou DK, Pham CD, Arthur K, Maxwell D, Peng Z, Leonard PG, Czako B, Pisaneschi F, Mandal P, Sun Y, Zielinski R, Pando SC, Wang X, Tran T, Xu Q, Wu Q, Jiang Y, Kang Z, Asara JM, Priebe W, Bornmann W, Marszalek JR, DePinho RA, Muller FL. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab. 2020 Nov 23. doi: 10.1038/s42255-020-00313-3. Epub ahead of print. PMID: 33230295. |
